Phase II Trial of Anti-Angiogenic Therapy With RT-PEPC in Patients With Relapsed Mantle Cell Lymphoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cyclophosphamide; Etoposide; Prednisone; Procarbazine; Rituximab; Thalidomide
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 28 Jun 2018 Biomarkers information updated
- 21 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 Jan 2008 The expected completion date for this trial is now 1 Dec 2009 as rported on ClinicalTrials.gov.